

CLAIMS ON APPEAL
(accompanying Appeal Brief of September 8, 2003)

U.S. Patent Application No. 10/083,565

7. (Amended) A method of treating hepatocellular carcinoma, said method comprising administering to a patient docetaxel in an amount sufficient to treat said hepatocellular carcinoma, wherein said administering is intravenous.

8. The method of claim 7, wherein said hepatocellular carcinoma is a fibrolamellar variant.

9. The method of claim 7, wherein said hepatocellular carcinoma is a mixed hepatocellular cholangiocarcinoma.

12. (Amended) The method of claim 7, wherein administration is by intravenous infusion.

16. The method of claim 7, wherein the patient is a human.

17. The method of claim 16, wherein said method comprises administering docetaxel in at least one dose of from 50 to 150 mg/m².

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER ^{LLP}

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

18. The method of claim 17, wherein said method comprises administering docetaxel in at least one dose of from 60 to 100 mg/m².

19. (Amended) The method of claim 17, wherein said method comprises administering docetaxel in at least one dose of 100 mg/m².

20. The method of claim 7, wherein said method comprises weekly administration until the desired therapeutic effect is obtained.

21. The method of claim 7, wherein said method comprises administration every three weeks until the desired therapeutic effect is obtained.

22. The method of claim 21, wherein said method comprises intravenously infusing docetaxel at a dose of 100 mg/m² over 1 hour every three weeks until the desired therapeutic effect is obtained.